Nuchal Translucency in First-Trimester Ultrasound Screening for Trisomy 21
|
|
|
- Sophie Waters
- 7 years ago
- Views:
Transcription
1 Nuchal Translucency in First-Trimester Ultrasound Screening for Trisomy 21 Jane Serene, MS3 Core Radiology Clerkship Beth Israel Deaconess Medical Center
2 Nuchal translucency-based screening for fetal abnormalities has truly become an indispensable aspect of contemporary obstetric practice. (Soha Said, Clinical Obstetrics and Gynecology, March 2008)
3 Agenda Introduction to Our Patients Definition of Nuchal Translucency and Measurement Criteria NT in Trisomy 21 Screening Advantages/Limitations of NT Screening Differential Diagnosis of Increased NT Mechanisms of Increased NT Fetal Anomalies associated with Increased NT Follow-up on Our Patients
4 Two Patients With Increased Fetal Risk for Trisomy 21 Our First Patient Our Second Patient 41 year-old, G5P2, with singleton pregnancy 40 year-old, G3P1, with singleton pregnancy Presents for early OB ultrasound (<14 weeks) Presents for early OB ultrasound Nuchal translucency = 4mm Nuchal translucency = 2.7mm
5 Defining Nuchal Translucency Fluid between skin and soft tissue at back of fetal neck Trans-abdominal OB U/S, sagittal view Can be seen sonographically in all first trimester fetuses Criteria for Increased NT: -NT > 3mm -Depends on gestational age (Most accurately expressed as multiple of the median) [3] Increased NT PACS, BIDMC
6 Criteria for NT Measurement (1) Trans-abdominal OB U/S, sagittal view PACS, BIDMC 1.Crown-Rump Length = 45-84mm (approximately 11-14wks). 14wks). 2.Mid-sagittal plane with fetus in neutral position: Neck flexion decreases NT; Neck extension increases NT.
7 Criteria for NT Measurement (2) Trans-abdominal OB U/S, sagittal view Findings: 1. Nasal Bone 2. Chin 3. Increased NT (4.2mm) PACS, BIDMC 3.Enlarge image: upper 2/3 of fetus. 4.Identify potential false positives: non-fused amnion, nuchal cord, neck extension. 5.Measure maximal translucency in greatest dimension: from outer soft tissue edge to inner nuchal membrane edge.
8 Inaccurate NT Measurement Trans-abdominal OB U/S, sagittal view 1. Not midline view: Nasal bone and chin not visible. 2. Difficult to separate fetal skin from amnion. BIDMC-PACS
9 How does Nuchal Translucency fit into screening for Trisomy 21?
10 The Combined Test Nuchal Translucency measurement between weeks Maternal Serum Markers 1.Free beta-hcg: Elevated in T21 2.Pregnancy-associated associated plasma protein A (PAPP-A): A): Decreased in T21
11 Practice Guidelines for Trisomy 21 Screening ACOG 2007: All women should be offered aneuploidy screening before 20wks gestation. -using maternal age alone to triage patients into diagnostic testing misses 50% of T21 pregnancies that occur in women <35 y/o. -noninvasive screening tests enable women to be more certain of their t actual risk for T21, which they can then weigh against the risk of invasive diagnostic testing. Ideal Screening: Combined Test in First Trimester with follow-up depending on results. Choose type of screening based on tests available in your area, patient s wishes, and patient s risk factors. ACOG Practice Bulletin 77: Screening for Fetal Chromosomal Abnormalities. Obstetrics and Gynecology. 109:1. Jan
12 Comparing Screening Methods for T21 Gestational Age Detection Rate/Sensitivity False Positive Rate Nuchal Translucency + Maternal Age Combined Test: Age + NT + PAPP-A A + Beta- hcg weeks 72-77% 77% 4.2-5% weeks 85% 4.8 Full Integrated Test: Combined Test + Quad Screen weeks weeks 85% 90-95% 95% 1% 2.6-5% Serum Integrated Test: PAPP-A A + Quad Screen (No U/S) weeks weeks 85% 3.5% Quad Screen: serum AFP, ue3, hcg, inhibin A weeks 85% 6.8% *All data from FASTER (First and Second Trimester Evaluation of Risk) and SURUSS (Serum, Urine and Ultrasound Screening Study) Trials. Barss VA et al. Overview of prenatal screening for Down syndrome. UpToDate <
13 Advantages of Screening with The Combined Test Abnormal Test First-trimester trimester identification of patients at high-risk for fetal anomalies. -Allows for early therapeutic abortion. -Enables pre-natal planning for care of affected child. Triage patients for further testing, which improves cost-effective use of resources. Normal Test Lowers overall risk of advanced maternal age patients. -Decreases use of invasive diagnostic procedures (CVS, amniocentesis) -Decreases procedure- associated fetal loss. Reduces anxiety.
14 Limitations of The Combined Test NT measurement is operator dependent and requires special training. A significant number of patients do not get prenatal care until the 2 nd trimester. 20% of obstetric patients are not being offered this test in spite of research demonstrating its efficacy. Anxiety-provoking when positive. If patients do not want CVS, they must wait 4 weeks for amniocentesis.
15 You identify a neck mass during first trimester ultrasound screening. What do you need to rule out before diagnosing increased nuchal translucency?
16 Differential Diagnosis: 1 st Trimester Neck Mass Hydrops Hydrops fetalis Cystic Cystic Hygroma Nonfused amnion Nuchal Nuchal cord Less Common: Branchial cleft cyst, hemangioma, neuroblastoma. Trans-abdominal OB U/S, axial view of fetal head Septated Cystic Hygroma Courtesy of Koeller KK, et al. Congenital Cystic Masses of the Neck: Radiologic-Pathologic Correlation. Radiographics, 1999;19:
17 Potential Mechanisms for Increased Nuchal Translucency 1.Heart strain/failure 2.Abnormal lymphatic drainage increased # or size of lymphatics, irregular connection between lymphatics and veins, impaired fetal movement. 3.Abnormal extracellular matrix Trans-abdominal OB U/S, sagittal view PACS, BIDMC
18 Fetal Abnormalities Associated with Increased NT Chromosomally Abnormal Trisomy 13 Trisomy 18 Trisomy 21 Turner s Syndrome Triploidy Unbalanced translocations Chromosomally Normal CNS defects Diaphragmatic hernia Omphalocele Myotonic Dystrophy Esophageal Atresia Infantile PCKD Achondroplasia Fetal Anemia Metabolic defects (and others)
19 Increased NT and Fetal Abnormalities: An Important Caveat Increased NT is NOT a fetal anomaly in and of itself. 90% of chromosomally normal fetuses with NT<4.5mm go on to be healthy, live-born infants. If there are no abnormalities on targeted ultrasound at weeks, there is no increased risk of poor outcome. There is no increased prevalence of developmental delay associated with increased NT.
20 Back to Our First Patient
21 Patient 1: Fetal Ultrasound Trans-abdominal OB U/S, sagittal view 41 y/o G5P2 Sent for early OB ultrasound to evaluate NT secondary to Advanced Maternal Age PAPP-A and beta-hcg levels unknown CRL =55.2mm PACS, BIDMC
22 Patient 1: NT Measurement on Fetal US Trans-abdominal OB U/S, midline sagittal view NT = 4.1mm PACS, BIDMC
23 Outcome for Our First Patient: Trisomy 21 Final NT Measurement = 4.0mm Follow-up: 1.Amniocentesis at 16 weeks: 47, XX, Full Fetal Survey at 21w6d: common AV canal. 3.Ultrasound at 33w2d: size<dates, oligohydramnios,, no duodenal atresia. 4.Uncomplicated delivery at 38w6d.
24 Patient 2: Fetal Ultrasound 40 y/o G3P1 Combined Test Results: 1.Decreased PAPP-A 2.Increased hcg 3.Ultrasound -CRL = 63.6mm Trans-abdominal OB U/S, sagittal view PACS, BIDMC
25 Patient 2: NT Measurement on Fetal US Trans-abdominal OB U/S, midline sagittal view NT = 2.7mm PACS, BIDMC
26 Outcome for Our Second Patient: Normal Fetus Final NT Measurement= 2.6mm Follow-up: 1.Full Fetal Survey at 16w0d: No abnormalities. 2.Patient declined amniocentesis. 3.Quad Screen at 19w1d: Lowered T21 risk 4.Delivered healthy baby girl at 40w5d.
27 Summary Nuchal Translucency, as part of the Combined Test, is an effective and accurate method of screening for fetal anomalies, especially Trisomy 21. Sensitive, non-invasive screening tests ensure that only those pregnancies at high-risk for abnormalities undergo invasive diagnostic procedures. Ultrasonographers must be carefully trained in NT measurement. All women who receive aneuploidy screening should be appropriately counseled and provided with thorough follow- up.
28 Acknowledgements Dr. Hope Ricciotti Maria Levantakis Dr. Prachi Dubey Dr. Rola Shaheen Dr. Colin McCardle Dr. Gail Birch Dr. Gillian Lieberman
29 Resources ACOG Practice Bulletin 77: Screening for Fetal Chromosomal Abnormalities. Obstetrics and Gynecology, 109:1. Jan Barss VA, et al. Overview of prenatal screening for Down syndrome. UpToDate (5/23/08) Benacerraf, BR. The sonographic diagnosis of fetal aneuploidy. UpToDate (5/16/08) Jackson M and Rose NC. Diagnosis and Management of Fetal Nuchal Translucency. Seminars in Roentgenology, Vol XXXIII, No 4. Oct. 1998: pp Koeller KK, et al. Congenital Cystic Masses of the Neck: Radiologic iologic-pathologic Correlation. Radiographics, 1999;19: Kurtz AB and Needleman L. American College of Radiology Standards: ds: Obstetrical Measurements. Seminars in Roentgenology, Vol XXXIII, No 4. Oct. 1998: pp Nyberg DA, et al. First-Trimester Screening. Radiologic Clinics of North America. 2006;44: Reeder, MM. Gamuts in Radiology: Comprehensive List of Roentgen Differential Diagnosis. 4 th Ed. New York: Springer, Said S, Malone FD. The Use of Nuchal Translucency in Contemporary ry Obstetric Practice. Clinical Obstetrics and Gynecology. 51:1. March 2008.
First Trimester Screening for Down Syndrome
First Trimester Screening for Down Syndrome What is first trimester risk assessment for Down syndrome? First trimester screening for Down syndrome, also known as nuchal translucency screening, is a test
The 11 13 +6 weeks scan
The 11 13 +6 weeks scan Kypros H. Nicolaides The 11 13 +6 weeks scan Fetal Medicine Foundation, London 2004 Dedication to Herodotos & Despina Contents Introduction 1. First trimester diagnosis of chromosomal
Obstetrical Ultrasound and Prenatal Diagnostic Center
Obstetrical Ultrasound and Prenatal Diagnostic Center Prenatal Diagnosis: Options and Opportunities Learn about various screening options including Early Risk Assessment (ERA), now available to women of
Non-Invasive Prenatal Testing (NIPT) Factsheet
Introduction NIPT, which analyzes cell-free fetal DNA circulating in maternal blood, is a new option in the prenatal screening and testing paradigm for trisomy 21 and a few other fetal chromosomal aneuploidies.
The California Prenatal Screening Program
The California Prenatal Screening Program Provider ook netic Disease Screening Program Quad Marker Screening Serum Integrated Screening Full Integrated Screening TABLE OF CONTENTS WELCOME to the California
fi АУ : fi apple Ав Ав АУ . apple, АУ fiав Ав. АК applefi АУ, АУАв Ав fi АУ apple fi Ав. А applefi АУ АУ АУ АсА» Ас Ам, длappleapple Ас...
АВАВАКдлАмА дла длама АсАядлАмА АВА АсдлАя & MАядлдлАмАК TА. 4, T. 2, АВ. 113-118, 2005 fi АУ : Аяapplefi. fiapple АсА» Ас Ам, длappleapple Ас..., Ая: Аяapplefi. fiapple, АВАУ Ас, АсА» Ас Ам длappleapple
Prenatal screening and diagnostic tests
Prenatal screening and diagnostic tests Contents Introduction 3 First trimester routine tests in the mother 3 Testing for health conditions in the baby 4 Why would you have a prenatal test? 6 What are
The ultrasound detection of chromosomal anomalies 1
The ultrasound detection of chromosomal anomalies 1 Werther Adrian Clavelli, MD 2, Silvia Susana Romaris de Clavelli, MD 2, Philippe Jeanty, MD, PhD 3 Adapted from The Ultrasound Detection of Chromosomal
CONFIDENT CODING FOR OB/GYN CONFIDENT CODING FOR OB/GYN
Arlene J. Smith, CPC AAPC National Advisory Board 2007-2009 1 So when exactly does the global period start? Unraveling the confusion in antepartum care coding Correct coding for multiple gestations! Vaginal
Clinical Studies Abstract Booklet
Clinical Studies Abstract Booklet The Harmony Prenatal Test is a non-invasive prenatal test (NIPT) that assesses the risk of trisomies by analyzing cell-free DNA (cfdna) in maternal blood. Since January
Screening for chromosomal abnormalities at 10 14 weeks: the role of ductus venosus blood flow
Ultrasound Obstet Gynecol 1998;12:380 384 Screening for chromosomal abnormalities at 10 14 weeks: the role of ductus venosus blood flow A. Matias*, C. Gomes*, N. Flack*, N. Montenegro and K. H. Nicolaides*
The California Prenatal Screening Program
The California Prenatal Screening Program Quad Marker Screening One blood specimen drawn at 15 weeks - 20 weeks of pregnancy (second trimester) Serum Integrated Screening Prenatal Patient Booklet - English
A test your patients can trust.
A test your patients can trust. A simple, safe, and accurate non-invasive prenatal test for early risk assessment of Down syndrome and other conditions. informaseq Prenatal Test Simple, safe, and accurate
Fetal Prognosis in Varix of the Intrafetal Umbilical Vein
Fetal Prognosis in Varix of the Intrafetal Umbilical Vein Waldo Sepulveda, MD, Antonio Mackenna, MD, Jorge Sanchez, MD, Edgardo Corral, MD, Eduardo Carstens, MD To assess the clinical significance of varix
A Guide to Prenatal Genetic Testing
Patient Education Page 29 A Guide to Prenatal Genetic Testing This section describes prenatal tests that give information about your baby s health. It is your choice whether or not to have these tests
Down s Syndrome: Ultrasound Screening
October 2001 Down s Syndrome: Ultrasound Screening Hilary Hochberg Advanced Radiology Clerkship Dr. Gillian Lieberman Patient M.C. 32 year old female presents at 16 weeks gestational age with abnormal
Maternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester
PRENATAL DIAGNOSIS Prenat Diagn 2000; 20: 390±394. Maternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester Kevin Spencer 1 *, Natasha Tul 2 and Kypros H. Nicolaides 2
Trisomies 13 and 18. -Maternal age. (Patau and Edward s syndrome)
Trisomies 13 and 18 (Patau and Edward s syndrome) Trisomy 21 (Down syndrome) is the commonest chromosomal disorder at birth, and has been considered in detail in previous annual reports 23. Other relatively
Genetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy
Genetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy Testing and pregnancy GP s role 3 Counselling before and during pregnancy 3 Collecting the family history
Clinical Significance of First Trimester Umbilical Cord Cysts
Clinical Significance of First Trimester Umbilical Cord Cysts Waldo Sepulveda, MD, Sergio Leible, MD, Angel Ulloa, MD, Milenko Ivankovic, MD, Carlos Schnapp, MD A cystic mass of the umbilical cord was
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free β-hcg and PAPP-A at 11 + 0to13+ 6 weeks
Ultrasound Obstet Gynecol 2006; 27: 151 155 Published online 30 December 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.2699 Screening for trisomy 21 by fetal tricuspid regurgitation,
LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES. Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD
LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD 2 Outline Genetics 101: Basic Concepts and Myth Busting Inheritance Patterns
Prenatal Testing Special tests for your baby during pregnancy
English April 2006 [OTH-7750] There are a number of different prenatal (before birth) tests to check the development of your baby. Each test has advantages and disadvantages. This information is for people
MASSIVELY PARALLEL SEQUENCING OF MATE RNAL PLASMA DNA IN 113 CASES OF FETAL NUCHAL CYSTIC HYGROMA
Scuola di specializzazione in Genetica Medica Journal Club 14 gennaio 2014 MASSIVELY PARALLEL SEQUENCING OF MATE RNAL PLASMA DNA IN 113 CASES OF FETAL NUCHAL CYSTIC HYGROMA Bianchi, Diana W. MD; Prosen,
Birth defects. Report by the Secretariat
EXECUTIVE BOARD EB126/10 126th Session 3 December 2009 Provisional agenda item 4.7 Birth defects Report by the Secretariat 1. In May 2009 the Executive Board at its 125th session considered an agenda item
Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies
No. 261 (Replaces No. 187, February 2007) Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies This clinical practice guideline has been prepared by the Genetics Committee of the Society of
Long-Term Prognosis of Pregnancies Complicated by Slow Embryonic Heart Rates in the Early First Trimester
Long-Term Prognosis of Pregnancies Complicated by Slow Embryonic Heart Rates in the Early First Trimester Peter M. Doubilet, MD, PhD, Carol B. Benson, MD, Jeanne S. Chow, MD Slow embryonic heart rates
your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing.
your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing. Accurate answers about your baby s health simply, safely, sooner. What is the verifi Prenatal
Frontomaxillary and mandibulomaxillary facial angles at 11 + 0to13+ 6 weeks in fetuses with trisomy 18
Ultrasound Obstet Gynecol 2007; 30: 928 933 Published online 1 November 2007 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.2/uog.5188 Frontomaxillary and mandibulomaxillary facial angles
cfdna in maternal plasma obtained from a population undergoing routine screening at 11-13 weeks gestation.
Reports of Major Impact www.ajog.org Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population Kypros H. Nicolaides, MD; Argyro Syngelaki, RM; Ghalia Ashoor, MD;
Ultrasonographic Diagnosis of Trisomy 18: Is It Practical in the Early Second Trimester?
Ultrasonographic Diagnosis of Trisomy 18: Is It Practical in the Early Second Trimester? Laurence E. Shields, MD, Leslie A. Carpenter, MS, CGC, Karin M. Smith, RDMS, Hanh V. Nghiem, MD The objective of
Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA
Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA Policy Number: Original Effective Date: MM.03.006 09/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
Department of Obstetrics and Gynecology, Kayseri Military Hospital, Kayseri, Turkey
Orıgınal Article Obstetrics & Gynecology North Clin Istanbul 2015;2(2):92-100 doi: 10.14744/nci.2015.08370 A prospective study to assess the clinical impact of interobserver reliability of sonographic
Ultrasound scans in pregnancy
Ultrasound scans in pregnancy www.antenatalscreening.wales.nhs.uk Copyright 2016 Public Health Wales NHS Trust. All rights reserved. Not to be reproduced in whole or in part without the permission of the
i_~~~~~~~~~~~~~~~~~~~~- A _L,"'...S.::.. E, pad - report of 92 cases with follow up of Antenatal diagnosis of cystic hygroma or nuchal survivors
F38 Archives ofdisease in Childhood 1996; 74: F38-F42 Antenatal diagnosis of cystic hygroma or nuchal pad - report of 92 cases with follow up of survivors P A Boyd, M Y Anthony, N Manning, C Lara Rodriguez,
Placenta, Cord, & Fluid
, Cord, & Fluid Abruption Accreta/Increta/Percreta Chorioangioma Complete Partial Not generally Relevant to U/S Gestational Age (Weeks) Distance from 16-23.9 24 to Internal Os >20 mm No No 11-20 mm 0-10
Prenatal Screening Policies in Europe
Prenatal Screening Policies in Europe 2010 EUROCAT Central Registry Room 12L09, University of Ulster Newtownabbey, Co Antrim Northern Ireland, BT37 0QB Tel: +44 (0)28 90366639 Fax: +44 (0)28 90368341 Email:
Sonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation
American Journal of Obstetrics and Gynecology (2006) 194, 397 401 www.ajog.org Sonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation Aris T. Papageorghiou, MD, a Kyriaki Avgidou, MD, a
Trisomy 13 (also called Patau s syndrome or T13)
Screening Programmes Fetal Anomaly Trisomy 13 (also called Patau s syndrome or T13) Information for parents Publication date: April 2012 Review date: April 2013 Version 2 117 Information sheet to help
First-trimester prenatal screening for Down syndrome and other aneuploidies AGENCE D ÉVALUATION DES TECHNOLOGIES ET DES MODES D INTERVENTION EN SANTÉ
First-trimester prenatal screening for Down syndrome and other aneuploidies AGENCE D ÉVALUATION DES TECHNOLOGIES ET DES MODES D INTERVENTION EN SANTÉ First-trimester prenatal screening for Down syndrome
Inclusion of Early Fetal Deaths in a Birth Defects Surveillance System
TERATOLOGY 64:S20 S25 (2001) Inclusion of Early Fetal Deaths in a Birth Defects Surveillance System MATHIAS B. FORRESTER AND RUTH D. MERZ* Hawaii Birth Defects Program, Honolulu, Hawaii 96817 ABSTRACT
journal of medicine The new england First-Trimester or Second-Trimester Screening, or Both, for Down s Syndrome abstract
The new england journal of medicine established in 1812 november 10, 2005 vol. 353 no. 19 First-Trimester or Second-Trimester Screening, or Both, for Down s Syndrome Fergal D. Malone, M.D., Jacob A. Canick,
Executive summary. Current prenatal screening
Executive summary Health Council of the Netherlands. NIPT: dynamics and ethics of prenatal screening. The Hague: Health Council of the Netherlands, 2013; publication no. 2013/34. In recent years, new tests
Cytogenetic and Molecular Diagnosis in Gestational Disorders
Cytogenetic and Molecular Diagnosis in Gestational Disorders Katherine Geiersbach, M.D. Assistant Professor, Department of Pathology University of Utah School of Medicine Medical Director, Cytogenetics
Universal Fetal Cardiac Ultrasound At the Heart of Newborn Well-being
Universal Fetal Cardiac Ultrasound At the Heart of Newborn Well-being Optimizes detection of congenital heart disease (chd) in the general low risk obstetrical population Daniel J. Cohen, M.D. danjcohen@optonline.net
Patient information on soft markers
Patient information on soft markers Before you read this section remember the following important points. The vast majority of babies with soft markers are normal. Soft markers are frequently seen in healthy
Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell-Free Fetal DNA
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions
Le dépistage prénatal First-trimester syndrome de Down. grossesse aneuploidies SUMMARY AGENCE D ÉVALUATION DES TECHNOLOGIES
Le dépistage prénatal du First-trimester syndrome de Down et prenatal d autres screening aneuploïdies au for premier Down trimestre syndrome de la and grossesse other aneuploidies SUMMARY AGENCE D ÉVALUATION
A test your patients can trust. A company you know and trust.
A test your patients can trust. A company you know and trust. informaseq Prenatal Test an advanced, non-invasive, prenatal screening for T21, T18, and T13 chromosomal aneuploidies using next generation
Knowledge and Perception of the Role of Targeted Ultrasound in Detecting Down Syndrome Among a High Risk Population
Texas Medical Center Library DigitalCommons@The Texas Medical Center UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 5-2011 Knowledge and Perception of the Role of
An OB US protocol book is available in the reading room to help you learn what is needed for problem cases.
HIGH RISK OBSTETRIC ULTRASOUND GUIDELINES Dolores H. Pretorius, M.D., Mary K. O Boyle M.D. and Lori Romine M.D. The obstetric ultrasound rotation is designed to emphasize an experience that relies on a
The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands
FVV in ObGyn, 2014, 6 (1): 7-12 Preliminary report The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands P.J. Willems 1, H. Dierickx 1, ES. Vandenakker
Prenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists Prenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy This statement has been
GE Healthcare VOLUSON 730 PRO The Diamond Release
GE Healthcare VOLUSON 730 PRO The Diamond Release imagination at work VOLUSON 730 PRO The Standard in Women's Healthcare 4D Dedication Dimensional Diagnostic Digital GE Healthcare continues to elevate
Genetics and Pregnancy Loss
Genetics and Pregnancy Loss Dorothy Warburton Genetics and Development (in Pediatrics) Columbia University, New York Estimates of Pregnancy Loss from Conception 1000 fertilized eggs (27% are lost) 728
Basic Human Genetics: Reproductive Health and Chromosome Abnormalities
Basic Human Genetics: Reproductive Health and Chromosome Abnormalities Professor Hanan Hamamy Department of Genetic Medicine and Development Geneva University Switzerland Training Course in Sexual and
CONGENITAL HEART DISEASE
CONGENITAL HEART DISEASE Introduction Congenital heart disease (CHD) is the most common congenital disorder in newborns [1]. Due to definitional issues, there are large variations in prevalence estimates.
Embryonic Heart Rate as a Prognostic Factor for Chromosomal Abnormalities
CME Article Embryonic Heart Rate as a Prognostic Factor for Chromosomal Abnormalities Deniz Oztekin, MD, Ozgur Oztekin, MD, Fatma I. Aydal, MD, Sivekar Tinar, MD, Zehra H. Adibelli, MD Objective. The purpose
New Prenatal Tests for Down Syndrome: Brian G. Skotko, MD, MPP Co-Director, Down Syndrome Program Massachusetts General Hospital
New Prenatal Tests for Down Syndrome: International Updates and What This All Means for Your Family Brian G. Skotko, MD, MPP Co-Director, Down Syndrome Program Massachusetts General Hospital Band of Angels
echocardiography practice and try to determine the ability of each primary indication to identify congenital heart disease. Patients and Methods
29 ABNORMAL CARDIAC FINDINGS IN PRENATAL SONOGRAPHIC EXAMINATION: AN IMPORTANT INDICATION FOR FETAL ECHOCARDIOGRAPHY? RIMA SAMI BADER Aim: The present study was conducted to evaluate the most common indications
Optional Tests Offered Before and During Pregnancy
Plano Women s Healthcare Optional Tests Offered Before and During Pregnancy Alpha-Fetoprotein Test (AFP) and Quad Screen These are screening tests that can assess your baby s risk of having such birth
Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers
DOI: 10.1002/pd.4019 ORIGINAL ARTICLE Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers Kevin Spencer* and Nicholas J. Cowans
Ultrasound evaluation of fetal gender at 12 14 weeks
Ultrasound evaluation of fetal gender at 12 14 weeks Marek Lubusky a,b, Martina Studnickova a, Ales Skrivanek a, Katherine Vomackova c, Martin Prochazka a Aims. The aim of this study was to assess the
Gutenberg Center in MALAGA
Introduction Gutenberg Center in MALAGA Gutenberg Center in Málaga opened in 1987 as a clinic to provide integral assisstance for women, divided into 6 Units, specialized in the different aspects of Obs
Sequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA
Sequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA Policy Number: Original Effective Date: MM.03.006 09/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 09/01/2013
First- and Second-Trimester Evaluation of Risk for Down Syndrome
Original Research First- and Second-Trimester Evaluation of Risk for Down Syndrome Robert H. Ball, MD, Aaron B. Caughey, MD, MPP, Fergal D. Malone, MD, David A. Nyberg, MD, Christine H. Comstock, MD, George
Triploidy. rarechromo.org
Triploidy rarechromo.org Triploidy Triploidy is a disorder that arises at conception when a baby starts life in the womb with a complete extra set of chromosomes. Chromosomes are the microscopically small
RECURRENT PREGNANCY LOSS DR.RAJALAKSHMI SRINIVASAN SPECIALIST GYNECOLOGIST ZULEKHA HOSPITAL DUBAI
RECURRENT PREGNANCY LOSS DR.RAJALAKSHMI SRINIVASAN SPECIALIST GYNECOLOGIST ZULEKHA HOSPITAL DUBAI RECURRENT PREGNANCY LOSS -RM Clinically recognized consecutive or non consecutive pregnancy losses before
PREGNANCY INFORMATION PACK. Peace of mind throughout pregnancy
PREGNANCY INFORMATION PACK Peace of mind throughout pregnancy Welcome Welcome to The 3fivetwo Group. We are delighted at the news of your recent pregnancy success and we wish you all the very best for
Evaluation and Follow-up of Fetal Hydronephrosis
Evaluation and Follow-up of Fetal Hydronephrosis Deborah M. Feldman, MD, Marvalyn DeCambre, MD, Erin Kong, Adam Borgida, MD, Mujgan Jamil, MBBS, Patrick McKenna, MD, James F. X. Egan, MD Objective. To
Risk Calculation Software Requirements for Down's Syndrome Screening
Screening Programmes Fetal Anomaly Risk Calculation Software Requirements for Down's Syndrome Screening Version 1 January 2013 Created by: Dave Wright, Barry Nix, Steve Turner, David Worthington and Andy
Choosing Wisely. Obstetrics / Maternal Fetal Medicine Things Providers and Patients Should Question
Choosing Wisely Obstetrics / Maternal Fetal Medicine Things Providers and Patients Should Question Michelle Owens, MD, FACOG David Rindfusz, MD, FACOG April Bleich, MD, FACOG Kathleen Crowley, MD 1 Discuss
National Down Syndrome Society
National Down Syndrome Society The national advocate for the value, acceptance and inclusion of people with Down syndrome What is Down Syndrome? Down syndrome is the most commonly occurring chromosomal
Clinical Policy: Ultrasound in Pregnancy Reference Number: CP.MP.38
Clinical Policy: Reference Number: CP.MP.38 Effective Date: 02/11 Last Review Date: 08/15 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory and
Prognosis of Very Large First-Trimester Hematomas
Case Series Prognosis of Very Large First-Trimester Hematomas Juliana Leite, MD, Pamela Ross, RDMS, RDCS, A. Cristina Rossi, MD, Philippe Jeanty, MD, PhD Objective. The aim of this study was to evaluate
CAGC Certification Logbook of Clinical Experience INSTRUCTIONS
CAGC Certification Logbook of Clinical Experience INSTRUCTIONS The purpose of the logbook is to show that the applicant has been significantly involved in the evaluation and counselling of patients seeking
A 28 year old woman, gravida 2, para 1, at 16 weeks gestation informs you that her cat, which she has owned for several years, has toxoplasmosis, as
A 28 year old woman, gravida 2, para 1, at 16 weeks gestation informs you that her cat, which she has owned for several years, has toxoplasmosis, as diagnosed from a stool sample. She is concerned about
SOFT FETAL ULTRASOUND FINDINGS
SOFT FETAL ULTRASOUND FINDINGS Compiled by the Genetics Team at The Credit Valley Hospital Last updated February 2008 Page 2 This document refers to the ultrasound finding of a soft sign, as compared
BELIEVE MIDWIFERY SERVICES, LLC
, LLC TITLE: ESTABLISHING the GESTATIONAL AGE & ROUTINE ULTRASOUND EFFECTIVE DATE: November 11th, 2013 POLICY STATEMENT Establishing accurate pregnancy dating impacts the management of normal and abnormal
1. PRENATAL DIAGNOSIS OF CHROMOSOMAL DISORDERS - molecular aspects
1. PRENATAL DIAGNOSIS OF CHROMOSOMAL DISORDERS - molecular aspects Ana Stavljenić-Rukavina Zagreb University School of Medicine, Croatia The standard measures for population health outcomes is based on
11 13 +6 Weeks Scan Project Newsletter
USA FETAL MEDICINE FOUNDATION OF THE UNITED STATES OF A MERICA Non-profit Registration No.1635069 July 2007 11 13 +6 Weeks Scan Project Naomi Greene MPH RDMS RDCS 3940 Laurel Canyon Blvd. #838 Studio City,
Prenatal Care Screening and Testing Guideline
Prenatal Care Screening and Testing Guideline Major Changes as of October 2013 2 Visit Schedule 2 Initial Visit 3 Second Trimester Visits (14 28 Weeks) 11 Third Trimester Visits (28 41 Weeks) 12 Postpartum
3D Ultrasound. Outline. What is 3D US? Volume Sonography. 3D Ultrasound in Obstetrics: Current Modalities & Future Potential. Alfred Abuhamad, M.D.
in Obstetrics: Current Modalities & Future Potential Outline What is 3D US? What are obvious advantages of 3D US? What is the future of 3D US? Alfred Abuhamad, M.D. Eastern Virginia Medical School 2D US
Population prevalence rates of birth defects: a data management and epidemiological perspective
Population prevalence rates of birth defects: a data management and epidemiological perspective Merilyn Riley Abstract The Victorian Birth Defects Register (VBDR) is a population-based surveillance system
The quadruple test screening for Down s syndrome and spina bifida
The quadruple test screening for Down s syndrome and spina bifida This leaflet provides information about a blood test to check for Down s syndrome and spina bifida. This test is available to you between
The National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report
0 The National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report Joan K Morris, Elizabeth De Souza December 2009 National Down Syndrome Cytogenetic Register Queen Mary University
What is the diagnostic value of ultrasound for determining a viable intrauterine pregnancy?
What is the diagnostic value of ultrasound for determining a viable intrauterine pregnancy? Full citation Sample size Tests Methods Results Limitations Steinkampf,M.P., Guzick,D.S., Hammond,K.R., Blackwell,R.E.,
Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register
1 Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register Joanne Gunby, M.Sc. CARTR Co-ordinator Email: gunbyj@mcmaster.ca Supported by the IVF Directors Group of
Neural tube defects: open spina bifida (also called spina bifida cystica)
Screening Programmes Fetal Anomaly Neural tube defects: open spina bifida (also called spina bifida cystica) Information for health professionals Publication date: April 2012 Review date: April 2013 Version
Aim of maternal-foetal care
Prenatal screening of Down s syndrom in the first and the second trimester of pregnancy Drahomira Springer ULBLD and 1.LF UK Praha Aim of maternal-foetal care the uncomplicated birth of a healthy baby
ETHICAL ISSUES OF PRENATAL SCREENING FOR DOWN S SYNDROME
ETHICAL ISSUES OF PRENATAL SCREENING FOR DOWN S SYNDROME PhD Thesis Adél Tóth, MA Department of Medical Genetics Medical Faculty University of Szeged, Hungary Szeged 2009 ii Table of contents List of publications
The First Trimester Screening program
The First Trimester Screening program The Fetal Medicine Foundation This guide has been designed to highlight the important clinical aspects of using the First Trimester Screening program. It is not intended
Genetic Counseling: A Profession in the Making. Jessica Hooks, MS Genetic Counselor University of South Carolina
Genetic Counseling: A Profession in the Making Jessica Hooks, MS Genetic Counselor University of South Carolina Definition the process of helping people understand and adapt to the medical, psychological
Increased fetal nuchal translucency at 11 14 weeks
PRENATAL DIAGNOSIS Prenat Diagn 2002; 22: 308 315. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/ pd.308 Increased fetal nuchal translucency at 11 14 weeks Kypros H.
INTERGROWTH-21 st International Fetal and Newborn Growth Standards for the 21 st Century
INTERGROWTH-21 st CRL standardization 1 INTERGROWTH-21 st International Fetal and Newborn Growth Standards for the 21 st Century The International Fetal and Newborn Growth Consortium Correct measurement
Fetal Lateral Ventricular Width: What Should Be Its Upper Limit?
Article Fetal Lateral Ventricular Width: What Should Be Its Upper Limit? A Prospective Cohort Study and Reanalysis of the Current and Previous Data Benny Almog, MD, Ronni Gamzu, MD, PhD, Reuven Achiron,
Ultrasonography of the Fetal Thyroid
Article Ultrasonography of the Fetal Thyroid Nomograms Based on Biparietal Diameter and Gestational Age Angela C. Ranzini, MD, Cande V. Ananth, PhD, MPH, John C. Smulian, MD, MPH, Michelle Kung, Anita
BIRTH DEFECTS IN MICHIGAN All Cases Reported and Processed by April 15, 2008
MICHIGAN DEPARTMENT OF COMMUNITY HEALTH Division for Vital Records and Health Statistics MICHIGAN BIRTH DEFECTS SURVEILLANCE REGISTRY BIRTH DEFECTS IN MICHIGAN All Cases Reported and Processed by April
Effect of incorrect gestational dating on Down s syndrome and neural tube risk assessment
Original Article Ann Clin Biochem 2001; 38: 230±234 Effect of incorrect gestational dating on Down s syndrome and neural tube risk assessment S N Millner From the Department of Pathology, University of
Information on the anomaly scan
Information on the anomaly scan The 20-week ultrasound August 2014 2 Contents 1. What can I find in this brochure? 5 2. Screening for physical defects 7 3. Abnormal test results 8 4. Making a conscious